MediPharm Labs (LABS) AI Stock Analysis

• Market Cap: $29.45M
• Dividend Yield: N/A
• Average Volume (3M): 275.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 17.74%
• EPS Growth: 37.61%
• Country: CA
• Employees: 161
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 420,755,000
• 10 Day Avg. Volume: 156,469
• 30 Day Avg. Volume: 275,853
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 0.43
• Enterprise Value/Gross Profit: 1.37
• Enterprise Value/Ebitda: -2.99
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall score reflects significant financial challenges, including negative profitability and cash flow issues. Technical indicators show a bearish trend, and valuation metrics highlight ongoing losses. These factors collectively contribute to a cautious outlook for MediPharm Labs.

MediPharm Labs Business Overview & Revenue Model

Company Description

MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

How the Company Makes Money

MediPharm Labs generates revenue primarily through the sale of cannabis oils and related products to both domestic and international markets. Key revenue streams include wholesale distribution to licensed retailers, direct sales to medical patients, and partnerships with other cannabis companies for product development and distribution. The company also benefits from long-term contracts and supply agreements, which provide a stable income base. Additionally, MediPharm Labs engages in research and development initiatives, potentially leading to new product lines and increased market share, further contributing to its overall earnings.

MediPharm Labs Financial Statement Overview

Summary

MediPharm Labs shows improving revenue and gross profit margins but faces persistent challenges with profitability and cash flow. The company maintains a strong equity position with minimal debt, offering financial stability. However, negative cash flows and net losses present ongoing risks.

Income Statement

The income statement shows a mixed performance with improving revenue growth and gross profit margins, but persistent negative net profit margins. The revenue growth rate from 2024 to TTM (Trailing-Twelve-Months) is 2.47%, indicating a slight increase. Gross profit margins improved from 30.52% in 2024 to 33.23% in TTM, showing better operational efficiency. However, the company continues to face significant net losses, with a net profit margin at -17.38% for TTM, highlighting ongoing profitability concerns.

Balance Sheet

The balance sheet reveals a strong equity position with a high equity ratio of 83.02% in TTM, indicating a stable financial foundation. The debt-to-equity ratio is minimal at 0.0029, showing limited reliance on debt financing. Return on equity remains negative at -17.28%, reflecting the company's challenges in generating returns for shareholders. Overall, the balance sheet shows financial stability but highlights the need for better profitability.

Cash Flow

Cash flow analysis highlights challenges with negative operating cash flow and free cash flow. The operating cash flow to net income ratio is 0.85, indicating some alignment between cash generation and reported earnings, despite being negative. Free cash flow to net income ratio is 0.87, showing that cash outflows are slightly less than reported net losses. The negative free cash flow growth rate from 2024 to TTM at -30.03% underscores ongoing liquidity constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.45M	41.96M	33.06M	22.12M	21.71M	36.01M
Gross Profit	14.03M	12.80M	5.86M	-1.91M	-15.25M	-43.98M
EBITDA	-6.45M	-7.52M	-10.48M	-27.09M	-38.55M	-53.40M
Net Income	-8.66M	-10.69M	-13.08M	-29.98M	-54.80M	-67.11M
Balance Sheet
Total Assets	49.31M	53.73M	63.94M	65.50M	92.36M	118.23M
Cash, Cash Equivalents and Short-Term Investments	10.36M	11.69M	17.98M	24.14M	34.11M	19.91M
Total Debt	542.00K	388.00K	2.29M	632.00K	216.00K	18.46M
Total Liabilities	9.49M	10.55M	10.93M	9.49M	9.21M	39.82M
Stockholders Equity	39.82M	43.18M	53.01M	56.01M	83.15M	78.41M
Cash Flow
Free Cash Flow	-7.67M	-5.01M	-12.81M	-16.93M	-14.00M	-45.28M
Operating Cash Flow	-7.51M	-4.86M	-12.34M	-16.07M	-13.21M	-37.77M
Investing Cash Flow	4.08M	413.00K	6.87M	5.16M	35.00K	-7.45M
Financing Cash Flow	-2.23M	-1.85M	-368.00K	796.00K	27.80M	26.42M

MediPharm Labs Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LABS, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.13 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LABS.

MediPharm Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DB	76 Outperform	74.97M	5.00	13.88%	―	-0.53%	―
VEXT	61 Neutral	86.03M	-3.07	-23.26%	―	36.50%	-306.47%
LABS	45 Neutral	$29.45M	―	-19.58%	―	17.74%	37.61%
IAN	43 Neutral	101.08M	25.00	11.65%	―	-4.39%	―
AVCN	42 Neutral	29.45M	-18.66	-50.26%	―	2.00%	80.83%
AYR.A	40 Underperform	18.10M	-0.04	-94.67%	―	0.63%	-31.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

MediPharm Labs Corporate Events

MediPharm Labs Achieves 14% Revenue Growth in Q2 2025

MediPharm Labs reported a 14% increase in Q2 2025 revenue, reaching $11.8 million, driven by a 50% growth in international medical cannabis sales, which now account for 57% of total revenue. Despite the financial impact of a proxy contest, the company maintained a strong cash balance and continues to focus on revenue growth and cost management to enhance profitability, demonstrating resilience in its commercial strategy.

MediPharm Labs Poised for Growth Amid Potential U.S. Cannabis Rescheduling

MediPharm Labs is uniquely positioned to capitalize on the potential rescheduling of cannabis in the United States, which could shift its classification from a Schedule I to a Schedule III drug. This change would facilitate expanded research and medical cannabis programs in the U.S. MediPharm’s existing FDA site registration and licensing, along with its experience in shipping cannabis products for research, place it at a competitive advantage to support the anticipated growth in U.S.-based cannabis research and medical programs.

MediPharm Labs to Announce Q2 2025 Financial Results

MediPharm Labs announced it will release its second quarter financial results for 2025 on August 14th, accompanied by a conference call and webcast. This announcement is part of the company’s ongoing efforts to maintain transparency with stakeholders and strengthen its position in the pharmaceutical cannabis industry. The company’s strategic acquisitions and compliance with international standards underscore its commitment to expanding its market reach and enhancing its operational capabilities.

MediPharm Labs Expands CBN Portfolio with New Nighttime Inhaler

MediPharm Labs has launched the Shake & Puff CBN THC Nighttime Inhaler in Canada, expanding its CBN oil product portfolio. This innovative, smoke-free inhaler offers a precise, fast-acting formulation designed for nighttime use, aligning with global trends towards smoke-free cannabinoid products. The launch strengthens MediPharm’s Canadian offerings and supports its strategy to scale precision cannabinoid delivery methods worldwide, reflecting consumer wellness trends and medical needs.

MediPharm Labs Announces 2025 Shareholder Meeting Results and Board Changes

MediPharm Labs announced the results of its 2025 Annual and Special Meeting of Shareholders, where key resolutions were approved, including setting the number of directors at seven and appointing MNP LLP as auditors. The company welcomed new directors Emily Jameson and John Medland, while acknowledging the contributions of outgoing director Michael Bumby. These changes, along with the approval of unallocated awards under the equity incentive plan, position MediPharm for future growth and stability, reinforcing its strategic direction and commitment to stakeholders.